Oncology in the Precision Medicine Era

This volume comprehensively reviews oncology in the precision medicine era of personalized care, latest developments in the field, and indications and clinical trials for the treatment of cancer with targeted therapies, immunotherapy, and epigenetic modulators. It thoroughly addresses concerns of various types of cancers including cancers of the head and neck, lung, colon, esophagus, bladder, pancreas, and breast; melanoma; multiple myeloma; hepatocellular carcinoma; renal cell carcinoma; and sarcomas. It is organized and written in a format that is easy to follow for both clinicians and non-clinical scientists interested in personalized medicine. Chapters cover the identification of the clinical problem and summary of recent findings, tumor biology and heterogeneity, genomics, examples of simple and complex cases, biological pathways, future clinical trials, and financial considerations.

Oncology in the Precision Medicine Era: Value-Based Medicine will serve as a useful resource for medical oncologists and healthcare providers tailoring medicine to the needs of the individual patient, from prevention and diagnosis to treatment and follow up. 

• oncology
• cancer
• precision medicine
• value-based oncology
• targeted therapies

• Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, USA

  Ravi Salgia

Ravi Salgia M.D., Ph.D. is the Arthur & Rosalie Kaplan Chair in Medical Oncology and the Associate Director for Clinical Sciences Research in City of Hope's Comprehensive Cancer Center. Prior to joining City of Hope, Dr. Salgia served as tenured professor of medicine, pathology and dermatology; director of the Thoracic Oncology Program and the Aerodigestive Tract Program Translational Research Lab in the section of hematology/oncology; vice chair for translational research in the department of medicine; and associate director for translational science at the University of Chicago Comprehensive Cancer Center in Chicago. Board-certified in both internal medicine and medical oncology, Dr. Salgia serves on various panels for the National Cancer Institute.  He has consistently received research grants from the NIH for his research work and has been awarded several invention discoveries and patents related to his work. He is the current Chief Editor for Cancer Commons, and the co-chief editor for the Journal of Carcinogenesis.  Dr. Salgia also serves on the editorial advisory board of four additional journals.  He has authored 286 peer-reviewed articles, reviews and editorials, one book, and 34 book chapters. 

Policies and ethics